Androstane derivatives--roxibolone and decylroxibolone--devoid of any affinity for the androgenic prostate and muscle receptors.
Unlike testosterone propionate and norandrostenolone decanoate, some new androstane derivatives did not cause any weight increase of the levator ani muscle and of the seminal vesicles in castrated rats. Actually, these new androsterone derivatives, characterized by the presence of a carboxyl group in the position 2 and a hydroxyl group in the 11 alpha or beta position, have entirely lost their affinity for the androgenic receptors of the prostate and of the skeletal muscles.
D000284:Administration, Oral; D000730:Androstadienes / Q000378:metabolism*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D007273:Injections, Intramuscular; D008297:Male; D009132:Muscles / Q000378:metabolism*; D009919:Orchiectomy; D011467:Prostate / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D011944:Receptors, Androgen / Q000378:metabolism*
D000730:Androstadienes; D011944:Receptors, Androgen; C044300:roxibolone; C035980:BR 917